Intus Biosciences Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
13
- Latest Deal Type
-
Series A2
- Latest Deal Amount
-
$2.1M
- Investors
-
7
Intus Biosciences General Information
Description
Developer of a microbiome testing and research platform designed to merge patented foundational science and sequencing technology. The company's platform allows the microbiome to be as critical to healthcare to overcome the challenges that hinder existing methods and provides unprecedented insights to physicians and patients, enabling healthcare professionals to identify bacteria and deliver answers about the microbiome with detail, accuracy, and scale.
Contact Information
Website
www.intusbio.comCorporate Office
- 400 Farmington Avenue
- CB 119
- Farmington, CT 06032
- United States
Corporate Office
- 400 Farmington Avenue
- CB 119
- Farmington, CT 06032
- United States
Intus Biosciences Timeline
Intus Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Later Stage VC (Series A2) | 15-May-2025 | $2.1M | Completed | Generating Revenue | ||
| 15. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 14. Later Stage VC | 16-Jul-2024 | Completed | Generating Revenue | |||
| 13. Later Stage VC | 16-Nov-2022 | Completed | Generating Revenue | |||
| 12. Later Stage VC | 07-Jan-2021 | Completed | Generating Revenue | |||
| 11. Later Stage VC | 27-May-2020 | Completed | Generating Revenue | |||
| 10. Debt - PPP | 07-Apr-2020 | Completed | Generating Revenue | |||
| 9. Early Stage VC | 14-Feb-2018 | Completed | Generating Revenue | |||
| 8. Grant | 01-Apr-2017 | $225K | $835K | Completed | Generating Revenue | |
| 7. Accelerator/Incubator | 01-Jan-2017 | $835K | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Intus Biosciences Comparisons
Industry
Financing
Details
Intus Biosciences Competitors (32)
One of Intus Biosciences’s 32 competitors is BiomeSense, a Venture Capital-Backed company based in Chicago, IL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BiomeSense | Venture Capital-Backed | Chicago, IL | ||||
| Viome Life Sciences | Venture Capital-Backed | Bellevue, WA | ||||
| Biosortia Microbiomics | Venture Capital-Backed | Dublin, OH | ||||
| Metafora | Venture Capital-Backed | Paris, France | ||||
| Nuanced Health | Venture Capital-Backed | Los Angeles, CA |
Intus Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Intus Biosciences Patents
Intus Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026231974-A1 | Systems and methods for disease assessment using microbiome profiling | Pending | 01-May-2025 | ||
| US-20260088169-A1 | System and method for detection of disease | Pending | 23-Sep-2024 | ||
| WO-2026064727-A1 | System and method for detection of disease | Pending | 23-Sep-2024 | ||
| WO-2020181082-A1 | Methods for cell lysis and preparation of high molecular weight dna from modified cells | Inactive | 07-Mar-2019 | ||
| AU-2019263364-A1 | Multiple specific/nonspecific primers for pcr of a complex gene pool | Inactive | 04-May-2018 | C12Q1/6851 |
Intus Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Intus Biosciences Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aimers Venture Partners | Venture Capital | Minority | ||
| VC23 Investors | Venture Capital | Minority | ||
| UConn Innovation Fund | Venture Capital | Minority | ||
| National Institute on Drug Abuse (NIDA) | Government | |||
| Accelerator for Biosciences in Connecticut | Accelerator/Incubator |
Intus Biosciences Acquisitions (1)
Intus Biosciences’s most recent deal was a Merger/Acquisition with Pattern Genomics. The deal was made on 15-Jun-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pattern Genomics | 15-Jun-2023 | Merger/Acquisition | Media and Information Services (B2B) |
Intus Biosciences FAQs
-
When was Intus Biosciences founded?
Intus Biosciences was founded in 2014.
-
Where is Intus Biosciences headquartered?
Intus Biosciences is headquartered in Farmington, CT.
-
What is the size of Intus Biosciences?
Intus Biosciences has 13 total employees.
-
What industry is Intus Biosciences in?
Intus Biosciences’s primary industry is Discovery Tools (Healthcare).
-
Is Intus Biosciences a private or public company?
Intus Biosciences is a Private company.
-
What is Intus Biosciences’s current revenue?
The current revenue for Intus Biosciences is .
-
How much funding has Intus Biosciences raised over time?
Intus Biosciences has raised $15.4M.
-
Who are Intus Biosciences’s investors?
Aimers Venture Partners, VC23 Investors, UConn Innovation Fund, National Institute on Drug Abuse (NIDA), and Accelerator for Biosciences in Connecticut are 5 of 7 investors who have invested in Intus Biosciences.
-
Who are Intus Biosciences’s competitors?
BiomeSense, Viome Life Sciences, Biosortia Microbiomics, Metafora, and Nuanced Health are some of the 32 competitors of Intus Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
